{"description":"National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03).","eventGroups":[{"deathsNumAffected":3,"deathsNumAtRisk":18,"description":"Durvalumab in combination with intensity-modulated radiotherapy (IMRT) treatments","id":"EG000","otherNumAffected":17,"otherNumAtRisk":18,"seriousNumAffected":1,"seriousNumAtRisk":18,"title":"Open-label, Single-arm"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Anemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Ear And Labyrinth Disorders - Other, Specify"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Hearing Impaired"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Tinnitus"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":18}],"term":"Hyperthyroidism"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Hypothyroidism"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":18}],"term":"Dry Mouth"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Dysphagia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Esophageal Stenosis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Gastroesophageal Reflux Disease"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Gastrointestinal Disorders - Other, Specify"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Mucositis Oral"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Oral Pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":18}],"term":"Fatigue"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Infections And Infestations - Other, Specify"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Alanine Aminotransferase Increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Aspartate Aminotransferase Increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Blood Bilirubin Increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Lipase Increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":18}],"term":"Lymphocyte Count Decreased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":18}],"term":"Serum Amylase Increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":18}],"term":"Weight Loss"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":18}],"term":"White Blood Cell Decreased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Hyponatremia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Bone Pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Fibrosis Deep Connective Tissue"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Pain In Extremity"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Dizziness"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":18}],"term":"Dysgeusia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Nervous System Disorders - Other, Specify"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Cough"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Dyspnea"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Laryngeal Edema"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Nail Loss"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Rash Maculo-Papular"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Skin And Subcutaneous Tissue Disorders - Other, Specify"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":18}],"term":"Hypertension"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":18}],"term":"Lymphedema"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Vascular Disorders - Other, Specify"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE v4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":18}],"term":"Vascular Disorders - Other, Specify"}],"timeFrame":"Adverse events were collected from day one of the study drug administration to 30 days after completion of treatment. (Up to 3 years)"}